NR 508 Midterm Exam | Advanced Pharmacology (2026)
Actual Q&A PDF | Chamberlain
1. Which of the following best describes the primary regulatory body for nurse
practitioner prescriptive authority?
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Correct Answer: The State Board of Nursing for each state
Rationale: Nurse practitioner prescriptive authority is regulated by the State Board of
Nursing in each individual state, not by national organizations or federal agencies like
the DEA. The scope of prescriptive authority, including autonomy and the breadth of
drugs that can be prescribed, is determined by the nurse practice act of the licensing
jurisdiction. This state-based regulation ensures that NP practice aligns with local laws
and professional standards.
2. What is the primary function of the cytochrome P450 enzyme system in
pharmacokinetics?
A) Facilitating the absorption of drugs from the gastrointestinal tract
B) Binding drugs to plasma proteins for distribution
C) Metabolizing drugs into more water-soluble compounds for excretion
D) Actively transporting drugs across the blood-brain barrier
Correct Answer: Metabolizing drugs into more water-soluble compounds for excretion
Rationale: The cytochrome P450 enzyme system is primarily responsible for the
metabolism of drugs, transforming them into more water-soluble metabolites that can
be readily excreted from the body. This phase of pharmacokinetics is crucial for drug
elimination and is subject to genetic polymorphisms that can significantly affect drug
response and toxicity. It does not primarily handle absorption, distribution, or active
transport across barriers.
3. According to the principles of pharmacodynamics, which term refers to the
maximum response a drug can produce?
A) Potency
B) Efficacy
C) Affinity
D) Therapeutic index
Correct Answer: Efficacy
,Rationale: Efficacy refers to the maximum therapeutic response that a drug can
produce, regardless of dose. Potency, in contrast, describes the amount of drug needed
to produce a given effect. Affinity is the strength of binding between a drug and its
receptor, while the therapeutic index is a measure of drug safety comparing toxic and
therapeutic doses. Understanding efficacy is essential for selecting the most
appropriate drug for a clinical condition.
4. A nurse practitioner is prescribing a drug with a narrow therapeutic index. Which
action is most important for ensuring patient safety?
A) Administering the drug with food to enhance absorption
B) Monitoring serum drug levels regularly
C) Prescribing the highest effective dose from the start
D) Avoiding concurrent use of any other medications
Correct Answer: Monitoring serum drug levels regularly
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses, necessitating regular monitoring of serum drug levels to
prevent toxicity and ensure efficacy. Administering with food, starting at the highest
dose, or avoiding all other medications are not standard approaches for all narrow-
therapeutic-index drugs and may not address the core safety concern of dose-related
toxicity.
5. In the context of drug development, which phase of clinical trials primarily aims
to establish safe dosages and pharmacokinetics in a small number of healthy
volunteers?
A) Phase I
B) Phase II
C) Phase III
D) Phase IV
Correct Answer: Phase I
Rationale: Phase I clinical trials are designed to establish the biological effects, safe
dosages, and pharmacokinetic properties of a new drug in a small number of healthy
volunteers. Phase II trials assess the drug's effectiveness in treating a disease in a small
number of patients, Phase III trials compare the new drug to standard therapy in larger
populations, and Phase IV involves post-marketing surveillance.
6. A patient's nutritional intake and laboratory results reflect hypoalbuminemia.
How does this condition most likely affect drug therapy?
A) It increases the volume of distribution for highly protein-bound drugs.
B) It decreases the risk of adverse drug reactions.
C) It enhances the metabolism of drugs by the liver.
D) It increases the renal excretion of active drug metabolites.
,Correct Answer: It increases the volume of distribution for highly protein-bound drugs.
Rationale: Hypoalbuminemia reduces the number of plasma protein binding sites,
leading to an increased free fraction of highly protein-bound drugs. This results in a
larger volume of distribution and a greater concentration of active drug at target sites,
which can increase the risk of adverse effects. It does not enhance metabolism or renal
excretion and typically increases, not decreases, the risk of adverse reactions.
7. Which of the following is a primary contraindication for the use of metformin in a
patient with type 2 diabetes mellitus?
A) Body mass index greater than 30
B) Glomerular filtration rate less than 30 mL/min
C) History of hypertension
D) Age over 65 years
Correct Answer: Glomerular filtration rate less than 30 mL/min
Rationale: Metformin is contraindicated in patients with severe renal impairment,
defined as a glomerular filtration rate less than 30 mL/min, due to the increased risk of
lactic acidosis, a rare but life-threatening condition. Obesity, hypertension, and
advanced age are not absolute contraindications but may require careful monitoring
and dose adjustment.
8. When prescribing an ACE inhibitor, the nurse practitioner must monitor for which
life-threatening adverse effect associated with increased bradykinin levels?
A) Hypokalemia
B) Nephrotoxicity
C) Angioedema
D) Tachycardia
Correct Answer: Angioedema
Rationale: ACE inhibitors prevent the breakdown of bradykinin, which can lead to
angioedema, a medical emergency characterized by swelling of the face, lips, and
airway. Hypokalemia is more commonly associated with diuretics, nephrotoxicity with
certain antibiotics or NSAIDs, and tachycardia is not a typical direct effect of ACE
inhibitors. Monitoring for angioedema is critical for patient safety.
9. A patient with a history of heart failure is prescribed digoxin. Which electrolyte
imbalance increases the risk of digoxin toxicity?
A) Hypokalemia
B) Hyperkalemia
C) Hypomagnesemia
D) Hypercalcemia
Correct Answer: Hypokalemia
, Rationale: Hypokalemia increases the risk of digoxin toxicity because potassium and
digoxin compete for binding sites on the sodium-potassium ATPase pump. When
potassium levels are low, more digoxin can bind, enhancing its toxic effects.
Hyperkalemia, hypomagnesemia, and hypercalcemia can also affect cardiac function
but hypokalemia is the most clinically significant electrolyte disturbance that
predisposes to digoxin toxicity.
10. Which principle explains why a drug with a high first-pass effect has low oral
bioavailability?
A) Extensive metabolism in the liver before reaching systemic circulation
B) Poor absorption from the gastrointestinal tract
C) High plasma protein binding
D) Rapid renal excretion of the parent drug
Correct Answer: Extensive metabolism in the liver before reaching systemic circulation
Rationale: The first-pass effect refers to the metabolism of a drug in the liver and gut wall
before it reaches systemic circulation, significantly reducing its oral bioavailability. Poor
absorption, high protein binding, and rapid renal excretion are distinct pharmacokinetic
factors that do not specifically define the first-pass effect. Understanding this principle
helps guide route selection and dosing.
11. A nurse practitioner is reviewing the medication list of an older adult patient.
Which age-related change most significantly increases the risk of adverse drug
reactions?
A) Increased gastric acidity
B) Decreased renal function
C) Increased lean body mass
D) Enhanced hepatic blood flow
Correct Answer: Decreased renal function
Rationale: Age-related decline in renal function reduces the clearance of drugs and their
metabolites, leading to drug accumulation and an increased risk of adverse effects.
Increased gastric acidity, increased lean body mass, and enhanced hepatic blood flow
are not typical age-related changes; in fact, gastric acidity often decreases, lean body
mass tends to decrease, and hepatic blood flow typically declines with age.
12. According to the DEA schedule of controlled substances, which schedule has the
highest potential for abuse while still having a currently accepted medical use?
A) Schedule I
B) Schedule II
C) Schedule III
D) Schedule IV
Actual Q&A PDF | Chamberlain
1. Which of the following best describes the primary regulatory body for nurse
practitioner prescriptive authority?
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Correct Answer: The State Board of Nursing for each state
Rationale: Nurse practitioner prescriptive authority is regulated by the State Board of
Nursing in each individual state, not by national organizations or federal agencies like
the DEA. The scope of prescriptive authority, including autonomy and the breadth of
drugs that can be prescribed, is determined by the nurse practice act of the licensing
jurisdiction. This state-based regulation ensures that NP practice aligns with local laws
and professional standards.
2. What is the primary function of the cytochrome P450 enzyme system in
pharmacokinetics?
A) Facilitating the absorption of drugs from the gastrointestinal tract
B) Binding drugs to plasma proteins for distribution
C) Metabolizing drugs into more water-soluble compounds for excretion
D) Actively transporting drugs across the blood-brain barrier
Correct Answer: Metabolizing drugs into more water-soluble compounds for excretion
Rationale: The cytochrome P450 enzyme system is primarily responsible for the
metabolism of drugs, transforming them into more water-soluble metabolites that can
be readily excreted from the body. This phase of pharmacokinetics is crucial for drug
elimination and is subject to genetic polymorphisms that can significantly affect drug
response and toxicity. It does not primarily handle absorption, distribution, or active
transport across barriers.
3. According to the principles of pharmacodynamics, which term refers to the
maximum response a drug can produce?
A) Potency
B) Efficacy
C) Affinity
D) Therapeutic index
Correct Answer: Efficacy
,Rationale: Efficacy refers to the maximum therapeutic response that a drug can
produce, regardless of dose. Potency, in contrast, describes the amount of drug needed
to produce a given effect. Affinity is the strength of binding between a drug and its
receptor, while the therapeutic index is a measure of drug safety comparing toxic and
therapeutic doses. Understanding efficacy is essential for selecting the most
appropriate drug for a clinical condition.
4. A nurse practitioner is prescribing a drug with a narrow therapeutic index. Which
action is most important for ensuring patient safety?
A) Administering the drug with food to enhance absorption
B) Monitoring serum drug levels regularly
C) Prescribing the highest effective dose from the start
D) Avoiding concurrent use of any other medications
Correct Answer: Monitoring serum drug levels regularly
Rationale: Drugs with a narrow therapeutic index have a small margin between
therapeutic and toxic doses, necessitating regular monitoring of serum drug levels to
prevent toxicity and ensure efficacy. Administering with food, starting at the highest
dose, or avoiding all other medications are not standard approaches for all narrow-
therapeutic-index drugs and may not address the core safety concern of dose-related
toxicity.
5. In the context of drug development, which phase of clinical trials primarily aims
to establish safe dosages and pharmacokinetics in a small number of healthy
volunteers?
A) Phase I
B) Phase II
C) Phase III
D) Phase IV
Correct Answer: Phase I
Rationale: Phase I clinical trials are designed to establish the biological effects, safe
dosages, and pharmacokinetic properties of a new drug in a small number of healthy
volunteers. Phase II trials assess the drug's effectiveness in treating a disease in a small
number of patients, Phase III trials compare the new drug to standard therapy in larger
populations, and Phase IV involves post-marketing surveillance.
6. A patient's nutritional intake and laboratory results reflect hypoalbuminemia.
How does this condition most likely affect drug therapy?
A) It increases the volume of distribution for highly protein-bound drugs.
B) It decreases the risk of adverse drug reactions.
C) It enhances the metabolism of drugs by the liver.
D) It increases the renal excretion of active drug metabolites.
,Correct Answer: It increases the volume of distribution for highly protein-bound drugs.
Rationale: Hypoalbuminemia reduces the number of plasma protein binding sites,
leading to an increased free fraction of highly protein-bound drugs. This results in a
larger volume of distribution and a greater concentration of active drug at target sites,
which can increase the risk of adverse effects. It does not enhance metabolism or renal
excretion and typically increases, not decreases, the risk of adverse reactions.
7. Which of the following is a primary contraindication for the use of metformin in a
patient with type 2 diabetes mellitus?
A) Body mass index greater than 30
B) Glomerular filtration rate less than 30 mL/min
C) History of hypertension
D) Age over 65 years
Correct Answer: Glomerular filtration rate less than 30 mL/min
Rationale: Metformin is contraindicated in patients with severe renal impairment,
defined as a glomerular filtration rate less than 30 mL/min, due to the increased risk of
lactic acidosis, a rare but life-threatening condition. Obesity, hypertension, and
advanced age are not absolute contraindications but may require careful monitoring
and dose adjustment.
8. When prescribing an ACE inhibitor, the nurse practitioner must monitor for which
life-threatening adverse effect associated with increased bradykinin levels?
A) Hypokalemia
B) Nephrotoxicity
C) Angioedema
D) Tachycardia
Correct Answer: Angioedema
Rationale: ACE inhibitors prevent the breakdown of bradykinin, which can lead to
angioedema, a medical emergency characterized by swelling of the face, lips, and
airway. Hypokalemia is more commonly associated with diuretics, nephrotoxicity with
certain antibiotics or NSAIDs, and tachycardia is not a typical direct effect of ACE
inhibitors. Monitoring for angioedema is critical for patient safety.
9. A patient with a history of heart failure is prescribed digoxin. Which electrolyte
imbalance increases the risk of digoxin toxicity?
A) Hypokalemia
B) Hyperkalemia
C) Hypomagnesemia
D) Hypercalcemia
Correct Answer: Hypokalemia
, Rationale: Hypokalemia increases the risk of digoxin toxicity because potassium and
digoxin compete for binding sites on the sodium-potassium ATPase pump. When
potassium levels are low, more digoxin can bind, enhancing its toxic effects.
Hyperkalemia, hypomagnesemia, and hypercalcemia can also affect cardiac function
but hypokalemia is the most clinically significant electrolyte disturbance that
predisposes to digoxin toxicity.
10. Which principle explains why a drug with a high first-pass effect has low oral
bioavailability?
A) Extensive metabolism in the liver before reaching systemic circulation
B) Poor absorption from the gastrointestinal tract
C) High plasma protein binding
D) Rapid renal excretion of the parent drug
Correct Answer: Extensive metabolism in the liver before reaching systemic circulation
Rationale: The first-pass effect refers to the metabolism of a drug in the liver and gut wall
before it reaches systemic circulation, significantly reducing its oral bioavailability. Poor
absorption, high protein binding, and rapid renal excretion are distinct pharmacokinetic
factors that do not specifically define the first-pass effect. Understanding this principle
helps guide route selection and dosing.
11. A nurse practitioner is reviewing the medication list of an older adult patient.
Which age-related change most significantly increases the risk of adverse drug
reactions?
A) Increased gastric acidity
B) Decreased renal function
C) Increased lean body mass
D) Enhanced hepatic blood flow
Correct Answer: Decreased renal function
Rationale: Age-related decline in renal function reduces the clearance of drugs and their
metabolites, leading to drug accumulation and an increased risk of adverse effects.
Increased gastric acidity, increased lean body mass, and enhanced hepatic blood flow
are not typical age-related changes; in fact, gastric acidity often decreases, lean body
mass tends to decrease, and hepatic blood flow typically declines with age.
12. According to the DEA schedule of controlled substances, which schedule has the
highest potential for abuse while still having a currently accepted medical use?
A) Schedule I
B) Schedule II
C) Schedule III
D) Schedule IV
